Program
enzalutamide
Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.
Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 313 open or running | phase 4since Oct 31, 2013 | Jan 18, 2011 | Apr 30, 2027phase 1 · NCT07783282 |
| Pfizerits history only | 162 open or running | phase 4since Nov 18, 2013 | Jul 31, 2007 | none ahead |
| Hinova Pharmaceuticals | 41 open or running | phase 3since Feb 17, 2019 | Dec 11, 2018 | none ahead |
| Alessa Therapeuticsits history only | 11 open or running | phase 1since Dec 14, 2023 | Dec 14, 2023 | Dec 30, 2028phase 1 · NCT06257693 |
| Applied Biologyits history only | 10 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Hinova Pharmaceuticals USAits history only | 10 open or running | phase 3since Feb 20, 2019 | Feb 20, 2019 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hinova Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2018First studies: 3 phase 1 studies in Metastatic Castration Resistant Prostate CancerFirst studyNCT03778047, NCT03776968, NCT03774056
- Feb 17, 2019Phase 3 study in MCRPCNCT03851640 · 417 planned · China
TargetBeta
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 4 Hinova Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03851640MCRPC · China | 3 | Recruiting | Sep 2025 | 417 |
| NCT03778047Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Oct 24, 2018 | 10 |
| NCT03776968Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Jan 15, 2018 | 47 |
| NCT03774056Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Sep 26, 2018 | 43 |
How it is read
Names in the registry
- “Enzalutamide”, 40 entries
- “enzalutamide”, 13 entries
- “MDV3100”, 8 entries
- “HC-1119”, 4 entries
- “HC1119”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 41 studies
- Neoplasms, 6 studies
- Breast Neoplasms, 5 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.